600056 中国医药
已收盘 10-29 15:00:00
资讯
新帖
简况
图解中国医药三季报：第三季度单季净利润同比下降73.88%
证券之星 · 01:07
图解中国医药三季报：第三季度单季净利润同比下降73.88%
股市必读：中国医药（600056）9月24日董秘有最新回复
证券之星 · 09-28
股市必读：中国医药（600056）9月24日董秘有最新回复
中国医药：全面推进科技创新
证券之星 · 09-24
中国医药：全面推进科技创新
中国医药：上半年度国际贸易板块实现主营业务收入24.59亿元，同比增长8.60%
证券之星 · 09-23
中国医药：上半年度国际贸易板块实现主营业务收入24.59亿元，同比增长8.60%
股市必读：中国医药（600056）9月22日董秘有最新回复
证券之星 · 09-23
股市必读：中国医药（600056）9月22日董秘有最新回复
中国医药：公司坚持稳中求进，以科技创新为引领，加快转型升级
证券之星 · 09-22
中国医药：公司坚持稳中求进，以科技创新为引领，加快转型升级
中国医药：公司获得的各类奖项是行业及社会对公司的认可
证券之星 · 09-22
中国医药：公司获得的各类奖项是行业及社会对公司的认可
花旗：中国医药工业转向创新驱动、质量导向发展 首选石药集团等
同花顺 · 09-21
花旗：中国医药工业转向创新驱动、质量导向发展 首选石药集团等
每周股票复盘：中国医药（600056）国贸板块H1营收24.59亿增8.6%
证券之星 · 09-20
每周股票复盘：中国医药（600056）国贸板块H1营收24.59亿增8.6%
广药集团李小军：中国医药企业出海，正从“产品输出”转向“生态协同”
凤凰网港股 · 09-16
广药集团李小军：中国医药企业出海，正从“产品输出”转向“生态协同”
中国医药：9月11日召开业绩说明会，投资者参与
证券之星 · 09-15
中国医药：9月11日召开业绩说明会，投资者参与
每周股票复盘：中国医药（600056）获业绩补偿款10,120.95万元
证券之星 · 09-13
每周股票复盘：中国医药（600056）获业绩补偿款10,120.95万元
中国医药（600056）披露聘任董事会秘书公告，9月8日股价上涨1.33%
证券之星 · 09-08
中国医药（600056）披露聘任董事会秘书公告，9月8日股价上涨1.33%
每周股票复盘：中国医药（600056）董秘变更由董事长代行职责
证券之星 · 09-06
每周股票复盘：中国医药（600056）董秘变更由董事长代行职责
股市必读：中国医药新发布《关于董事会秘书离任的公告》
证券之星 · 09-03
股市必读：中国医药新发布《关于董事会秘书离任的公告》
中国医药（600056）披露董事会秘书离任公告，9月1日股价上涨0.44%
证券之星 · 09-01
中国医药（600056）披露董事会秘书离任公告，9月1日股价上涨0.44%
中国医药步入黄金时代
证券市场周刊 · 09-01
中国医药步入黄金时代
每周股票复盘：中国医药（600056）股东户数下降3.43%，中报净利降15.26%
证券之星 · 08-30
每周股票复盘：中国医药（600056）股东户数下降3.43%，中报净利降15.26%
中国医药（600056）2026年中报简析：净利润同比下降15.26%
证券之星 · 08-27
中国医药（600056）2026年中报简析：净利润同比下降15.26%
股市必读：中国医药中报 - 第二季度单季净利润同比下降44.88%
证券之星 · 08-27
股市必读：中国医药中报 - 第二季度单季净利润同比下降44.88%
暂无数据
公司概况
公司名称：
中国医药健康产业股份有限公司
所属行业：
批发业
上市日期：
1997-05-15
主营业务：
中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是医药研发、医药工业、医药商业、医疗器械、国际贸易、中药大健康、电商业务。报告期内，公司入选药智网“2026化药研发实力TOP100”第72位。
发行价格：
7.02
{"stockData":{"symbol":"600056","market":"SH","secType":"STK","nameCN":"中国医药","latestPrice":8.87,"timestamp":1793257200000,"preClose":8.88,"halted":0,"volume":7670760,"delay":0,"changeRate":-0.0011,"floatShares":1495000000,"shares":1496000000,"eps":0.207,"marketStatus":"已收盘","change":-0.01,"latestTime":"10-29 15:00:00","open":8.86,"high":8.9,"low":8.78,"amount":67852700,"amplitude":0.0135,"askPrice":8.87,"askSize":475,"bidPrice":8.86,"bidSize":296,"shortable":0,"etf":0,"ttmEps":0.207,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1793323800000},"marketStatusCode":5,"adr":0,"adjPreClose":8.88,"symbolType":"stock","openAndCloseTimeList":[[1793237400000,1793244600000],[1793250000000,1793257200000]],"highLimit":9.77,"lowLimit":7.99,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1495879748,"isCdr":false,"pbRate":1.11,"roa":"--","peRate":42.850242,"roe":"2.08%","epsLYR":0.3164,"committee":-0.44394,"marketValue":13268000000,"turnoverRate":0.0051,"status":1,"floatMarketCap":13264000000},"requestUrl":"/m/hq/s/600056/tweets","defaultTab":"tweets","newsList":[{"id":"2679876052","title":"图解中国医药三季报：第三季度单季净利润同比下降73.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679876052","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679876052?lang=zh_cn&edition=full","pubTime":"2026-10-30 01:07","pubTimestamp":1793293671,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药2026年三季报显示，前三季度公司主营收入249.89亿元，同比下降3.5%；归母净利润2.91亿元，同比下降35.99%；扣非净利润2.68亿元，同比下降32.13%；其中2026年第三季度，公司单季度主营收入80.37亿元，同比下降8.86%；单季度归母净利润4200.24万元，同比下降73.88%；单季度扣非净利润3702.49万元，同比下降73.3%；负债率62.37%，投资收益1734.34万元，财务费用1.63亿元，毛利率10.42%。财报数据概要请见下图:本文数据来源于中国医药2026年三季报，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000003010.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03069","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670401110","title":"股市必读：中国医药（600056）9月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2670401110","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670401110?lang=zh_cn&edition=full","pubTime":"2026-09-28 03:39","pubTimestamp":1790537950,"startTime":"0","endTime":"0","summary":"截至2026年9月24日收盘，中国医药报收于8.86元，下跌1.12%，换手率0.5%，成交量7.49万手，成交额6649.31万元。董秘最新回复投资者： 请问公司三季度是否会开业绩说明会，投资者急着与公司交流董秘： 您好！当日关注点交易信息汇总：9月24日主力资金净流入73.17万元，占总成交额1.1%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092800001729.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK1610","BK0010","600056","BK0082","03069","BK0028","BK0175","BK0188","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669635144","title":"中国医药：全面推进科技创新","url":"https://stock-news.laohu8.com/highlight/detail?id=2669635144","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669635144?lang=zh_cn&edition=full","pubTime":"2026-09-24 16:30","pubTimestamp":1790238636,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药(600056)09月24日在投资者关系平台上答复投资者关心的问题。投资者提问：联合湖北丽益、则正科技同步推进前沿创新药研发进程,请问这个创新药具体指的是？中国医药回复：您好！公司全面推进科技创新，在仿制药、改良型新药、创新药研究方面均有布局。则正医药建立了复杂注射剂技术、难溶性药物增溶递送技术、缓控释技术、药械组合技术、儿童药物研发创新技术、速释制剂技术、口服多肽技术以及原料合成技术八大核心自主研发平台；丽益科技专注于化学药物、中药及天然药物、药物新制剂、新工艺以及保健品研发。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092400028204.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0028","BK0082","03069","BK0175","BK0188","600056","BK0010","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669610950","title":"中国医药：上半年度国际贸易板块实现主营业务收入24.59亿元，同比增长8.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2669610950","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669610950?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:30","pubTimestamp":1790152227,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药(600056)09月23日在投资者关系平台上答复投资者关心的问题。投资者提问：3月2日的中国医药保健品进出口商会交流，公司营收实现了较块增长，请问近年公司营收不断萎缩，这个较快增长指的是什么？既然实现了较快增长为什么二季度主业务板块基本都下降中国医药回复：您好！公司持续深耕重点海外市场，积极拓展进口内贸业务，上半年度国际贸易板块实现主营业务收入24.59亿元，同比增长8.60%。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300027774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","600056","BK0175","BK0082","BK0188","BK0250","BK0185","03069","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669712999","title":"股市必读：中国医药（600056）9月22日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2669712999","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669712999?lang=zh_cn&edition=full","pubTime":"2026-09-23 01:46","pubTimestamp":1790099178,"startTime":"0","endTime":"0","summary":"截至2026年9月22日收盘，中国医药报收于9.05元，下跌0.55%，换手率0.54%，成交量8.14万手，成交额7383.58万元。董秘最新回复投资者： 近期看到公司获得了不少奖项，增强了公司的实力，公司业绩应该蒸蒸日上？投资者： 1.第24届世界制药原料中国展，则正医药携复杂制剂、儿药、口服缓控释等六大核心技术平台亮相，吸引众多新老客户、行业同仁驻足交流。当日关注点交易信息汇总：9月22日主力资金净流出767.29万元，占总成交额10.39%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092300002327.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03069","BK0188","BK0250","BK0175","BK0185","BK0082","BK0028","BK0010","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669211201","title":"中国医药：公司坚持稳中求进，以科技创新为引领，加快转型升级","url":"https://stock-news.laohu8.com/highlight/detail?id=2669211201","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669211201?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:25","pubTimestamp":1790065519,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药(600056)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：近期看到有投资者质疑公司的奋斗目标和导向，请问公司如何打消投资者的质疑？中国医药回复：您好！公司坚持稳中求进，以科技创新为引领，加快转型升级。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200027418.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","03069","BK0028","BK0010","BK0188","BK0175","600056","BK0082","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669056112","title":"中国医药：公司获得的各类奖项是行业及社会对公司的认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2669056112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669056112?lang=zh_cn&edition=full","pubTime":"2026-09-22 16:24","pubTimestamp":1790065463,"startTime":"0","endTime":"0","summary":"证券之星消息，中国医药(600056)09月22日在投资者关系平台上答复投资者关心的问题。投资者提问：近期看到公司获得了不少奖项，增强了公司的实力，公司业绩应该蒸蒸日上？请问公司近期的业绩如何？这些奖项有没有起到作用？中国医药回复：您好！公司获得的各类奖项是行业及社会对公司的认可，有助于提升公司品牌形象与行业影响力。公司将持续深耕主业，把品牌荣誉转化为经营动力。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092200027330.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0010","BK0188","BK0250","BK0185","BK0175","BK0082","BK0028","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669153741","title":"花旗：中国医药工业转向创新驱动、质量导向发展 首选石药集团等","url":"https://stock-news.laohu8.com/highlight/detail?id=2669153741","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669153741?lang=zh_cn&edition=full","pubTime":"2026-09-21 15:23","pubTimestamp":1789975380,"startTime":"0","endTime":"0","summary":"花旗发布研报称，工信部等部门联合发布《医药工业发展“十五五”规划》，核心是推动中国医药工业由规模驱动增长转向创新驱动、质量导向发展，并明确提出到2030年跻身世界领先行列的目标。规 ...","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/hks/20260921/c680121029.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/hks/20260921/c680121029.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["600056","BK0188","BK0175","BK0028","BK0185","BK0250","BK0082","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668909545","title":"每周股票复盘：中国医药（600056）国贸板块H1营收24.59亿增8.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668909545","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668909545?lang=zh_cn&edition=full","pubTime":"2026-09-20 02:01","pubTimestamp":1789840869,"startTime":"0","endTime":"0","summary":"截至2026年9月18日收盘，中国医药报收于8.94元，较上周的8.91元上涨0.34%。本周，中国医药9月14日盘中最高价报8.99元。9月16日盘中最低价报8.8元。中国医药当前最新总市值133.73亿元，在医药商业板块市值排名7/32，在两市A股市值排名1424/5220。2026年上半年，公司国际贸易板块实现主营业务收入24.59亿元，同比增长8.60%。2026年上半年，公司深入践行乡村振兴战略，立足武川中药材资源，推动帮扶由“输血”转向长效“造血”。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092000000499.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03069","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667467425","title":"广药集团李小军：中国医药企业出海，正从“产品输出”转向“生态协同”","url":"https://stock-news.laohu8.com/highlight/detail?id=2667467425","media":"凤凰网港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667467425?lang=zh_cn&edition=full","pubTime":"2026-09-16 12:07","pubTimestamp":1789531649,"startTime":"0","endTime":"0","summary":"广州医药集团党委书记、董事长李小军出席论坛，并发表主题演讲。李小军表示，当下全球健康产业格局正深刻重塑，中国医药企业的出海模式也正经历从产品输出向生态协同的深度迭代。过去讲出海，更多是把产品卖到全球。但现在，中国医药产业规模已稳居世界第二，在研新药管线约占全球三成，一线创新药研发正从跟跑走向并跑。只靠单品输出，已经不足以支撑真正的全球化，李小军给出的方向是生态出海。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://original.ifeng.com/c/8wSoePaEkdG","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0082","BK0185","BK0010","BK0175","600056","BK0250","BK0028","BK0188","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667616875","title":"中国医药：9月11日召开业绩说明会，投资者参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2667616875","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667616875?lang=zh_cn&edition=full","pubTime":"2026-09-15 13:07","pubTimestamp":1789448833,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年9月14日中国医药发布公告称公司于2026年9月11日召开业绩说明会。现在半年度业绩披露，营业收入只有170亿。2026年上半年，公司深入践行乡村振兴战略，立足武川中药材资源，推动帮扶由“输血”转向长效“造血”。中国医药主营业务：国际贸易业务,医药商业业务,医疗器械业务,医药工业业务,大健康和电商业务。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091500018110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0175","BK0028","600056","BK0082","03069","BK0010","BK0185","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667003455","title":"每周股票复盘：中国医药（600056）获业绩补偿款10,120.95万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2667003455","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667003455?lang=zh_cn&edition=full","pubTime":"2026-09-13 03:00","pubTimestamp":1789239631,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，中国医药报收于8.91元，较上周的9.06元下跌1.66%。本周，中国医药9月8日盘中最高价报9.18元。本周关注点公司公告汇总：中国医药收到业绩补偿款本息合计10,120.95万元。公司公告汇总中国医药健康产业股份有限公司于2026年9月7日召开第十届董事会第7次会议，审议通过聘任张琳女士为公司董事会秘书，任期自董事会决议通过之日起至第十届董事会届满。案件判决已生效并进入执行阶段，涉案金额为13,940.41万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000865.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","03069","BK0250","BK0175","BK0188","BK0028","BK0010","BK0185","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665032189","title":"中国医药（600056）披露聘任董事会秘书公告，9月8日股价上涨1.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2665032189","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665032189?lang=zh_cn&edition=full","pubTime":"2026-09-08 17:57","pubTimestamp":1788861455,"startTime":"0","endTime":"0","summary":"截至2026年9月8日收盘，中国医药报收于9.17元，较前一交易日上涨1.33%，最新总市值为137.17亿元。中国医药健康产业股份有限公司于2026年9月7日召开第十届董事会第7次会议，审议通过聘任张琳女士为公司董事会秘书，任期自董事会决议通过之日起至第十届董事会届满。公司已就本次聘任向上海证券交易所完成备案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800028222.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","03069","BK0028","BK0188","BK0185","600056","BK0250","BK0175","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665366324","title":"每周股票复盘：中国医药（600056）董秘变更由董事长代行职责","url":"https://stock-news.laohu8.com/highlight/detail?id=2665366324","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665366324?lang=zh_cn&edition=full","pubTime":"2026-09-06 03:14","pubTimestamp":1788635652,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，中国医药报收于9.06元，较上周的9.28元下跌2.37%。本周，中国医药8月31日盘中最高价报9.27元。本周关注点公司公告汇总：董事会秘书袁精华因工作调整辞职，辞职后继续担任公司副总经济师，由董事长代行董事会秘书职责。其辞职自送达董事会之日起生效。截至公告日，袁精华先生未持有公司股票，不存在未履行完毕的公开承诺。公司董事会对袁精华先生在任职期间所作贡献表示感谢。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600001052.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0175","BK0082","BK0010","600056","BK0250","BK0188","03069","BK0185","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664456128","title":"股市必读：中国医药新发布《关于董事会秘书离任的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664456128","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664456128?lang=zh_cn&edition=full","pubTime":"2026-09-03 02:01","pubTimestamp":1788372080,"startTime":"0","endTime":"0","summary":"公司公告汇总关于董事会秘书离任的公告中国医药董事会于2026年9月1日收到董事会秘书袁精华的书面辞职函，其因工作调整申请辞去该职务，辞职自送达董事会之日起生效；辞职后袁精华继续担任公司副总经济师；截至公告日，其未持有公司股票，无未履行完毕的公开承诺；董事会秘书空缺期间，由公司董事长代行相关职责。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090300001902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","BK0010","600056","BK0082","03069","BK0028","BK0175","BK0188","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664857989","title":"中国医药（600056）披露董事会秘书离任公告，9月1日股价上涨0.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664857989","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664857989?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:42","pubTimestamp":1788273740,"startTime":"0","endTime":"0","summary":"近日，中国医药健康产业股份有限公司发布《关于董事会秘书离任的公告》。公告显示，公司董事会于2026年9月1日收到董事会秘书袁精华先生的书面辞职函，因工作调整原因，袁精华先生申请辞去公司董事会秘书职务，辞职后将继续担任公司副总经济师。其辞职自送达董事会之日起生效。截至公告日，袁精华先生未持有公司股票，不存在未履行完毕的公开承诺。公司董事会对袁精华先生在任职期间所作贡献表示感谢。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090100043251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","BK0175","BK0185","BK0082","BK0010","03069","BK0028","BK0188","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664882099","title":"中国医药步入黄金时代","url":"https://stock-news.laohu8.com/highlight/detail?id=2664882099","media":"证券市场周刊","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664882099?lang=zh_cn&edition=full","pubTime":"2026-09-01 10:16","pubTimestamp":1788228975,"startTime":"0","endTime":"0","summary":"七月以来，A股生物医药板块迅速走强。与前几次创新药一枝独秀不同，本轮行情呈现创新药与CXO“双星闪耀”态势，多只个股创近五年股价新高。这得益于企业基本面改善、估值修复、地缘风险缓释及政策利好的叠加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609013861234285.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609013861234285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0185","BK0010","BK0028","BK0188","BK0250","03069","BK0082","BK0175","600056"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663043115","title":"每周股票复盘：中国医药（600056）股东户数下降3.43%，中报净利降15.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663043115","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663043115?lang=zh_cn&edition=full","pubTime":"2026-08-30 08:08","pubTimestamp":1788048497,"startTime":"0","endTime":"0","summary":"截至2026年8月28日收盘，中国医药报收于9.28元，较上周的9.2元上涨0.87%。本周，中国医药8月26日盘中最高价报9.5元。中国医药当前最新总市值138.82亿元，在医药商业板块市值排名6/32，在两市A股市值排名1368/5211。本周关注点股本股东变化：股东户数较上期减少3.43%，户均持股上升至1.2万股。第二季度单季主营收入87.63亿元，同比上升2.51%；单季归母净利润6691.42万元，同比下降44.88%；单季扣非净利润5316.83万元，同比下降43.65%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083000004159.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0250","BK0175","BK0188","03069","BK0082","600056","BK0028","BK0185"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662740312","title":"中国医药（600056）2026年中报简析：净利润同比下降15.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662740312","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662740312?lang=zh_cn&edition=full","pubTime":"2026-08-27 06:02","pubTimestamp":1787781737,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期中国医药发布2026年中报。根据财报显示，中国医药净利润同比下降15.26%。截至本报告期末，公司营业总收入169.52亿元，同比下降0.73%，归母净利润2.49亿元，同比下降15.26%。按单季度数据看，第二季度营业总收入87.63亿元，同比上升2.51%，第二季度归母净利润6691.42万元，同比下降44.88%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700010794.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600056","03069"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662749516","title":"股市必读：中国医药中报 - 第二季度单季净利润同比下降44.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2662749516","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662749516?lang=zh_cn&edition=full","pubTime":"2026-08-27 02:20","pubTimestamp":1787768423,"startTime":"0","endTime":"0","summary":"业绩披露要点：2026年第二季度单季度归母净利润6691.42万元，同比下降44.88%。业绩披露要点财务报告2026年中报显示，上半年度主营收入169.52亿元，同比下降0.73%；归母净利润2.49亿元，同比下降15.26%；扣非净利润2.31亿元，同比下降9.81%；第二季度单季度主营收入87.63亿元，同比上升2.51%；单季度归母净利润6691.42万元，同比下降44.88%；单季度扣非净利润5316.83万元，同比下降43.65%；负债率62.69%，投资收益1252.66万元，财务费用1.25亿元，毛利率10.86%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700006817.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["03069","600056"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793305058190,"stockEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.0103},{"period":"3month","weight":-0.0722},{"period":"6month","weight":-0.1365},{"period":"1year","weight":-0.2013},{"period":"ytd","weight":-0.134}],"compareEarnings":[{"period":"1week","weight":-0.0018},{"period":"1month","weight":-0.0467},{"period":"3month","weight":-0.0472},{"period":"6month","weight":-0.112},{"period":"1year","weight":-0.0909},{"period":"ytd","weight":-0.08}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"中国医药健康产业股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"123915人(较上一季度减少0.53%)","perCapita":"12067股","listingDate":"1997-05-15","address":"北京市丰台区西营街1号院1区1号楼25-28层","registeredCapital":"149587万元","survey":" 中国医药健康产业股份有限公司的主营业务是医药领域的生产、加工和贸易。公司的主要产品是医药研发、医药工业、医药商业、医疗器械、国际贸易、中药大健康、电商业务。报告期内，公司入选药智网“2026化药研发实力TOP100”第72位。","listedPrice":7.02},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"中国医药,600056,中国医药股票,中国医药股票老虎,中国医药股票老虎国际,中国医药行情,中国医药股票行情,中国医药股价,中国医药股市,中国医药股票价格,中国医药股票交易,中国医药股票购买,中国医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"中国医药(600056)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供中国医药(600056)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}